Back

Semaglutide and cardiovascular outcomes in patients with overweight or obesity and heart failure: A pre-specified analysis from the SELECT trial

14 May 2024 (08:54 - 09:02)
Organised by: Logo
Congress Presentation Part of: Late breaking clinical trials II Pharmacotherapy HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Professor John Eric Deanfield

University College London, London (United Kingdom of Great Britain & Northern Ireland)

9 More presentations in this session

Presentation thumbnail
Transendocardial injection of autologous expanded CD34+ Stem Cells (ProtheraCytes) promotes reverse cardiac remodeling in patients with left ventricular dysfunction after acute myocardial infarction
Professor F. Zannad (Vandoeuvre-Les-Nancy, FR)
Slides Video
Presentation thumbnail
Discussant review - EXCELLENT
Professor F. Gustafsson (Pleasanton, US)
Slides Video
Presentation thumbnail
Bio-ADM as a marker for residual congestion and early rehospitalization in patients hospitalized for acute heart failure; data from STRONG-HF
Mr G. Voordes (Groningen, NL)
Slides Video
Presentation thumbnail
Discussant review - STRONG-HF
Professor A. Bayes Genis (Badalona, ES)
Slides Video
Presentation thumbnail
Discussant review - SELECT
Professor P. Jhund (Glasgow, GB)
Slides Video

Access the full session

Session thumbnail
Late breaking clinical trials II
Video

The Event

Event poster

Heart Failure 2024

14 May 2024 08:54 CET
You may be interested in
thumbnail
Congress Presentation
Discussant review - SELECT
thumbnail
Congress Session
Late breaking clinical trials II

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources